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Introduction
Fatal if untreated, human African
trypanosomiasis (HAT; sleeping sickness)
afflicts an estimated 50,000–70,000 people
each year [1], all in sub-Saharan Africa,
with only a minority of cases (nearly
12,000 in 2008) being reported [2]. HAT
is one of four neglected tropical diseases
(NTDs) identified by the World Health
Organization (WHO) as requiring Inno-
vative and Intensified Disease Manage-
ment (IDM), along with Chagas disease,
leishmaniasis, and Buruli ulcer [3]. These
particular NTDs have poorly understood
burdens, lack optimal control tools, receive
insufficient research and development
(R&D) investment, and affect people who
often live in remote or insecure areas with
limited access to health care. Excluding
Buruli ulcer, these IDM diseases have the
highest death rates of all NTDs [4].
HAT in west and central Africa is
caused by the protozoan parasite Trypano-
soma brucei gambiense, transmitted through
tsetse flies. The disease progresses from
first stage (infecting blood and lymph) to
second stage (infecting the central nervous
system), which can lead to severe sleep
disturbances, neurological and psychiatric
disorders, coma, and death. Primary
elements of HAT management are sur-
veillance, diagnosis, treatment, and vector
control.
Drug treatments for T. b. gambiense HAT
have been limited: pentamidine for first-
stage disease, and melarsoprol or eflor-
nithine for second-stage disease. Eflor-
nithine is safer and often more effective
than melarsoprol, which is associated with
high toxicity, even fatal at times, and
exhibits high rates of treatment failure in
numerous HAT-endemic foci. However,
despite an increasing proportion of sec-
ond-stage HAT treated with eflornithine
during recent years [5], melarsoprol re-
mains in use in many treatment centers
due to eflornithine’s long, burdensome
treatment administration requirements,
which are difficult to implement in re-
source-constrained settings.
In April 2009, a new treatment option,
nifurtimox-eflornithine combination ther-
apy (NECT), was added to the WHO
Essential Medicines List (EML) for the
treatment of second-stage T. b. gambiense
HAT [6]. NECT was added to the EML
based on the high efficacy and good
safety profile observed in all studies done
to date, against a background of recog-
nized severity of stage 2 disease and
toxicity of existing treatments. Surveil-
lance of adverse events was strongly
recommended [7]. Compared with eflor-
nithine monotherapy, NECT is easier to
administer and requires fewer human
and material resources. In the current
context, NECT stands as the most
promising first-line treatment for sec-
ond-stage T. b. gambiense HAT. Here we
describe the developments and challenges
in rolling out and implementing NECT
in HAT-endemic areas.
NECT Development
History
In response to the lack of new drug
entities for HAT treatment, and the
inadequate and undesirable features of
existing drugs, new alternative therapies
needed to be assessed. Based on the known
utility of combination therapies in attenu-
ating toxicity, maintaining or increasing
efficacy, and preventing resistance, this
avenue was explored by evaluating drug
combinations including eflornithine and
melarsoprol, along with nifurtimox, a drug
used to treat another trypanosomal illness,
Chagas disease (American trypanosomia-
sis), and shown to have varying efficacy
against HAT [8–10].
From 2001 through 2004, Epicentre,
the research and epidemiology arm of
Me ´decins Sans Frontie `res/Doctors With-
out Borders (MSF), conducted two se-
quential clinical drug-combination studies
at HAT treatment sites in northern
Uganda, which revealed the potential of
the nifurtimox-eflornithine combination as
a highly effective and well-tolerated ther-
apy [11,12]. Based on these initial studies,
Epicentre and MSF launched in the
Republic of Congo (RoC) a demonstration
trial comparing this therapy to the best
available therapy at the time, intravenous
eflornithine for 14 days [13].
This study was completed through a
multicentric extension in the Democratic
Republic of Congo (DRC), in collabora-
tion with the countries’ ministries of health
(MOHs), the Drugs for Neglected Diseases
initiative (DNDi), and the Swiss Tropical
Institute (STI; now known as Swiss
Tropical and Public Health Institute
[Swiss TPH]). The whole multicentric
study extended from 2003 through 2008.
The combination of nifurtimox and eflor-
nithine was found to be a marked im-
provement for second-stage HAT therapy,
with key advantages over the previous
therapeutic options [14,15].
Advantages
In the randomized, open-label, phase
III trial at four centers in DRC and RoC,
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ister than, and noninferior in efficacy to,
eflornithine monotherapy for the treat-
ment of second-stage T. b. gambiense HAT
[14]. The drug combination was fairly well
tolerated: patients treated with NECT had
half as many major drug-related adverse
events as those treated with eflornithine
alone (14% versus 29%; P=0.002). The
noninferiority in efficacy of NECT versus
eflornithine monotherapy (as measured by
10% difference in cure rates) was demon-
strated by 96.5% cure rate for NECT
group versus 91.6% for eflornithine group
in the intention-to-treat patient popula-
tion, and 97.7% versus 91.7% in the per-
protocol population, both at 18 months
follow-up.
While eflornithine monotherapy re-
quires 56 intravenous (IV) infusions over
14 days, NECT requires only 14 infusions
over 7 days (plus oral nifurtimox 3 times
per day for 10 days). NECT’s shorter
treatment duration and considerably fewer
IV infusions make its administration less
difficult and cumbersome for both the
patients and care providers.
The cost of NECT kits (supplies and
preparation time; excluding the cost of the
drugs, which are donated) is J39 per
patient, compared with J107 per patient
for eflornithine monotherapy kits (unpub-
lished data, MSF-Logistique, February
2010). This large cost difference is due to
fewer quantities of drugs, injection fluids,
and other materials, resulting in less
volume and weight to transport (four
NECT treatments per kit, compared with
two eflornithine monotherapy treatments
per kit). Cost differences may be even
larger when taking into account indirect
expenditures such as shorter lengths of
hospital stay, transport of lighter kits to the
endemic country’s capital and from the
capital to the field, and management of
fewer adverse events.
When comparing the cost of NECT
against melarsoprol, a simple cost com-
parison would be inappropriate because of
melarsoprol’s high toxicity and declining
effectiveness. A cost-effectiveness study
showed that the cost per life saved was
similar between melarsoprol and standard
eflornithine monotherapy [16]. It is there-
fore reasonable to assume that NECT’s
cost per life saved will be lower than that
of melarsoprol, though this requires fur-
ther study.
As a combination of drugs with different
modes of action, NECT also has less
potential for emergence of parasitic resis-
tance, which is a major drawback of long-
term use of monotherapies, as shown with
melarsoprol [17].
New Research
Further data on the safety, effectiveness,
and feasibility of NECT are expected from
the NECT-FIELD study, which com-
menced April 2009 and is currently
recruiting patients [18]. This multicenter,
open-label phase IIIb study is being
carried out by DNDi in association with
Swiss TPH and the national HAT control
program of DRC, Programme National
de Lutte contre la Trypanosomiase Hu-
maine Africaine (PNLTHA). An estimated
620 patients will be treated with NECT
under field conditions at regular treatment
centers in DRC run by PNLTHA and
nongovernmental organizations.
Implementing NECT in the Field
Recent and Ongoing Developments
The addition of NECT to the WHO
EML in April 2009 has paved the way for
its rollout and implementation in affected
countries. NECT is provided free of
charge by WHO through MSF-Logis-
tique, the logistics and supplies division
of MSF. Because nifurtimox is not regis-
tered for use for HAT, the WHO first
requires country MOHs to sign disclaimer
letters, in which the MOH takes legal
responsibility for the off-label use of the
drug.
Despite initial fears that this disclaimer
letter prerequisite could present an obsta-
cle to NECT use [19], the MOHs of
Central African Republic (CAR), Chad,
DRC, Equatorial Guinea, south Sudan,
and Uganda have signed the letters at the
time of this writing. Other countries have
expressed the same intentions and appear
to be close to signing soon, including
Angola and RoC. These seven countries
(excluding Equatorial Guinea) have the
highest burdens of HAT, reporting 98.8%
of all cases of T. b. gambiense HAT in 2006
[2]. Country-level acceptance of NECT
has therefore been positive, and accep-
tance by other countries where HAT is
present should translate into concrete,
rapid improvement in the field. Physician
and patient acceptance of NECT is also
important and should be followed.
With disclaimer letters signed, MOH
requests to WHO for NECT drugs and
supplies have begun. For example, DRC
ordered and received 1,000 NECT kits in
November 2009, with more orders placed
since, and CAR ordered and received 250
kits.
MSF-Logistique assembles and ships the
NECT kits from its headquarters in
Me ´rignac, France, near Bordeaux
(Figure 1). The kits, designed in collabo-
ration between MSF-Logistique and
WHO, include all the drugs, fluids, and
medical materials for the treatment pro-
tocol. The drugs are donated by the
manufacturers. In September 2009, Bayer
agreed to donate 400,000 tablets of
nifurtimox per year to WHO through
2014. Aventis and later sanofi-aventis have
donated eflornithine to WHO through
two consecutive 5-year agreements since
2001. Kits are being made available free of
charge to countries by WHO, with
financial support from sanofi-aventis cov-
ering the costs of materials and transport
to the capital of each country. Each 41-kg
kit contains four full treatments of NECT.
The volume per NECT treatment is
reduced by more than half compared to
eflornithine monotherapy.
The first WHO-sponsored medical
training session for administering NECT
was held in November 2009 in Kinshasa,
DRC, for French-speaking countries, with
ten representatives from Cameroon, CAR,
Chad, DRC, Guinea, and RoC. Another
NECT training session took place in
February 2010 in Omugo, Uganda, for
Uganda and south Sudan. More training
modules are planned in 2010 in French,
Portuguese, and English.
Current and Future Challenges
Wide-scale delivery of NECT faces a
number of challenges, some specific to
NECT, and others related to HAT
treatment and control in general.
Getting rid of melarsoprol as first-
line treatment of stage 2 T. b.
gambiense HAT. One of the key
challenges for NECT implementation is
to replace the use of melarsoprol with
NECT as first-line treatment for second-
stage T. b. gambiense HAT. A derivative of
arsenic and highly toxic, melarsoprol use is
associated with frequent serious adverse
events and unacceptably high case-fatality
rates. Nevertheless, melarsoprol remains
widely used for second-stage T. b. gambiense
HAT where eflornithine is not available or
practical [20]. According to a 2008
assessment of eight provinces in DRC,
50% of patients with second-stage HAT
were still being treated with melarsoprol
(with the other half treated with
eflornithine monotherapy) (unpublished
data, PNLTHA). Alarmingly, in one
district, Bandundu, which had the
heaviest HAT caseload of the provinces
surveyed, 96% of second-stage HAT
patients were still treated with
melarsoprol.
Melarsoprol injections are often painful
for patients. Severe adverse events are
frequently associated with its use, particu-
larly the development of reactive enceph-
alopathy in 5%–10% of patients, of whom
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with melarsoprol is also a serious concern
in various disease foci in several countries,
with reports of relapse rates up to 59%
[25–27]. Treatment failures include re-
lapse (or probable relapse), lack of re-
sponse to treatment, or death. These
failures suggest the emergence of parasitic
resistance to melarsoprol [17].
Donors, policymakers, and national
programs should now aim for the with-
drawal of melarsoprol as first-line treat-
ment for second-stage T. b. gambiense HAT
with the shortest possible delay. In en-
demic areas where treatment with melar-
soprol is still predominant, NECT proto-
col change and training should be
prioritized. Country-by-country analyses
and forecasts will be needed to assess
NECT implementation, with comparisons
to melarsoprol use. The use of melarsoprol
should soon be restricted to treat relapses
of T. b. gambiense HAT after initial first-line
treatment with NECT or eflornithine, and
to treat second-stage HAT due to T. b.
rhodesiense.
Transport and supply. Logistical
difficulties of getting NECT kits to the
field are a concern. The timely transport
of treatment kits within endemic countries,
from the capital to the hospitals and clinics
in the field, remains a common bottleneck.
Drug supply and access are perpetual
issues for NTD treatment programs. The
donations of nifurtimox and eflornithine
from the drug manufacturers are most
welcome and must be sustained for NECT
to be widely implemented.
Training. Although relatively simpler
and safer than the older HAT treatment
protocols, the training needs for NECT
are still considerable in treatment centers
that have not yet used eflornithine. Care
providers must be trained in the correct
nursing care of IV catheters, precise and
time-dependent IV administration of
eflornithine, daily oral administration of
nifurtimox under surveillance (directly
observed treatment [DOT]), monitoring
of adverse events, and follow-up. DOT is
important to ensure treatment adherence
in patients who are often mentally
disturbed (due to the neurological effects
of stage 2 infection), in a low educational
level context, and/or at risk of vomiting
the tablets. Less-intense training is needed
in places where eflornithine monotherapy
has already been introduced, since the
NECT protocol is similar but simpler.
Vertical approaches still needed in
some areas. Current NTD donor and
policy discussions include a strong focus on
program integration into existing primary
health care structures [28]. Integration
may indeed be ideal for control of NTDs,
including for HAT. However, in practice
this ‘‘one size fits all’’ strategy may not be
feasible for HAT given the complex
heterogeneity of its epidemiology and the
lack of appropriate diagnostic and
treatment tools. Many HAT-endemic
areas are in remote, rural areas or in
regions of conflict and insecurity, with
little or no health infrastructure in which
to integrate.
In these contexts, obstacles to HAT
diagnosis and treatment, including inte-
gration into primary health care systems,
are therefore expected. One major hurdle
lies in the complexity and sophistication of
HAT diagnostic algorithms and treatment
administration (including NECT), which
often exceed the capacities of health
centers and district hospitals in resource-
constrained settings where HAT is endem-
ic. Another impediment is the physical and
logistical difficulties in reaching some of
the affected populations.
A strong vertical component thus re-
mains necessary for HAT surveillance and
case management, particularly in areas
where the disease is uncontrolled. Active
case finding (including mass screening) for
T. b. gambiense followed by treatment is a
highly recommended control measure in
such areas. Access to laboratory testing is
necessary for screening and diagnosis,
which involves resource-intensive proce-
dures including lumbar punctures. Inter-
vening in conflict zones to reach patients
trapped by violence is a major challenge.
Context-appropriate program approaches
that take into account the complex
epidemiology of HAT and the precarious
situations in which it is found are still
necessary. An example is described in
Box 1.
Limitations of NECT
NECT has a number of limitations as a
treatment option for HAT. It is likely less
effective against T. b. rhodesiense HAT,
which badly needs different and better
drugs for both stages of the disease.
Administration of NECT is relatively
complicated, including the requirement
of two IV infusions per day for one week.
Although this protocol is shorter and
simpler than eflornithine monotherapy,
and safer than melarsoprol, it is still
Figure 1. Preparation of a nifurtimox-eflornithine combination therapy (NECT) kit at
MSF-Logistique, Me ´rignac, France. Photo credit: V. Carlier/MSF-Logistique.
doi:10.1371/journal.pntd.0000720.g001
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simpler regimen, preferably based on an
oral drug formulation, is desirable. A
treatment effective for both disease stages
may eliminate the need for painful lumbar
punctures and difficult examination of the
cerebrospinal fluid, which are currently
performed for HAT staging.
NECT’s limitations highlight the ideal
features desired in a new drug for HAT
treatment [29]:
N Safe, low toxicity
N Oral, or noninjectable
N Effective in both HAT disease stages
N Effective against both types of trypano-
somal parasites: T. b. gambiense and
rhodesiense
N Short treatment duration
N Minimal training needs, readily im-
plementable
N Affordable
Discussion and Conclusions
The development, acceptance, and
initial rollout of NECT have been exciting
and emboldening advances for HAT
treatment. Efficient NECT delivery must
now be sustained to ensure this new
therapeutic option reaches all patients in
need.
Continuous wide-scale utilization of the
toxic drug melarsoprol and of eflornithine
in monotherapy, which may trigger para-
sitic resistance to this life-saving drug,
highlight the urgency of replacing existing
treatments with NECT for second-stage T.
b. gambiense HAT.
Even if wide-scale NECT delivery is
achieved, better drugs and diagnostics are
still required to improve HAT control.
R&D of new drugs is underway by a
number of groups. In September 2009,
DNDi entered a phase I clinical trial of a
drug candidate given orally for HAT,
fexinidazole [30]. Currently this is the
only new drug candidate in clinical
development for HAT. More drug com-
pounds are needed in the R&D pipeline.
R&D for better diagnostic tools for
HAT are also needed. The sensitivity of
parasite detection tools in body fluids is
currently limited [31,32]. In addition,
diagnosis of trypanosomal infection of the
central nervous system requires a lumbar
puncture, which is painful and difficult to
perform, especially in resource-con-
strained settings. Field-adapted, rapid
diagnostic tests for HAT diagnosis and
staging must be developed if complete
HAT control, including integration into
primary health care centers, is to be
feasible. The introduction of novel bio-
markers, including recently identified
markers for disease staging [33], and the
development of field-adapted tests will
require the mobilization of research labo-
ratories with adequate funding.
Although there has been recent dis-
course that the elimination of HAT is
feasible, this lofty goal is not likely to be
possible in the near future given ongoing
constraints, namely the difficulties of
implementing complex diagnostic–treat-
ment algorithms in resource-poor areas
of high endemicity and persistent security
threats. Even if perfect treatment and
diagnostic tools were readily available for
HAT, certain patient populations would
still be difficult or impossible to reach.
HAT control in these hotspots should
therefore be addressed through targeted
programming and access, with robust
surveillance and response. International
donors and policymakers should be made
aware that a ‘‘one size fits all’’ integrated
approach may not be suitable for HAT in
certain contexts and with the current tools.
Dedicated funding for diagnosis and
treatment and R&D, as well as allocated
national program funding, must be put
forth and sustained. The current paucity
of international donors funding HAT
control national programs is highly worri-
some. Still and in the future, continued
political pressure and will are needed for
the prioritization of HAT patient care.
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